Aspirin resistance: Focus on clinical endpoints

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 6, 2008, Pages 475-484

  Pusch, Gabriella ^a   Feher, Gergely ^a,e   Kotai, Katalin ^b   Tibold, Antal ^c   Gasztonyi, Beata ^d   Feher, Andrea ^a   Papp, Elod ^d   Lupkovics, Geza ^d   Szapary, Laszlo ^a  

^a Department of Neurology ^*  (Hungary)

^b 1St Department of Medicine   (Japan)

^c UNIVERSITY OF PÉCS   (Hungary)

^d Zala County Hospital   (Hungary)

^e UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Antiplatelet agent; Aspirin; Aspirin resistance; Cardiovascular outcome; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; APROTININ; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RESVERATROL; THROMBOXANE A2; TICLOPIDINE; TIROFIBAN; ANTITHROMBOCYTIC AGENT;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME; BLEEDING TIME; BLOOD; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; DRUG RESISTANCE; EVIDENCE BASED MEDICINE; INSTRUMENTATION; METHODOLOGY; NOMENCLATURE; PREDICTION AND FORECASTING; REPRODUCIBILITY; STANDARD; THROMBOCYTE ADHESIVENESS;

ASPIRIN; BLEEDING TIME; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TERMINOLOGY AS TOPIC; THROMBOXANE A2; TREATMENT OUTCOME;

EID: 59449107938     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31818eee5f     Document Type: Review

References (68)

1. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324: 71-86.
3. Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother. 2005;6: 2027-2045.
4. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006; 367: 606-617.
5. Lordkipanidzé M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702-1708.
6. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function. results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115:3156-3164.
7. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance, Platelet Physiology Subcommittee of the Scientific and Standardization Committee, International Society on Thromb Haemost. J Thromb Haemost. 2005; 3:1309 -1311.
8. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007; 167:1593-1599.
9. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195-198.
10. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost. 2007;5(Suppl 1):230-237.
11. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-1234.
12. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980-1987.
13. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102:449-461.
14. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischaemic myocardium. Cardiovasc Res. 2004;61:498-511.
15. Andrews RK, Gardiner EE, Shen Y, et al. Platelet interactions in thrombosis. IUBMB Life. 2004;56:13-18.
16. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101;1206-1218.
17. Eikelboom JW, Hirsh J, White JI, et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at risk of high for cardiovascular event. Circulation. 2002;105:1650-1655.
18. Bruno A, McConnell JP, Cohen SN, et al. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. Stroke. 2004;35:727-730.
19. Valles J, Santos MT, Fuset MP, et al. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2007;99:19-25.
20. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993;71:397-403.
21. Buchanan MR, Schwartz L, Bourassa M, et al. Results of the BRAT study-a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol. 2000; 16:1385-1390.
22. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41: 961-965.
23. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J.2004;147:293-300.
24. Berrouschot J, Schwetlick B, von Twickel G, et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand. 2006;113:31-35.
25. Faraday N, Braunstein JB, Heldman AW, et al. Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. Platelets. 2004;15:9-14.
26. Zhang Y, Liang J, Zhou YJ, et al. Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi. 2005;33: 695-659.
27. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol. 2005;46:1705-1709.
28. Cornelissen J, Kirtland S, Lim E, et al. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost. 2006;95:476-482.
29. Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirintreated patients. J Thromb Haemost. 2006;4:1271-1278.
30. Stejskal D, Václav́ik J, Lacnák B, et al. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med. 2006;17: 349-354.
31. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006;47:27-33.
32. Geisler T, Kapp M, Göhring-Frischholz K, et al. Residual platelet activity is increased in Clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart. 2007 Jun 13 [Epub ahead of print]
33. Kundu SK, Heilmann E, Sio R, Garcia C, et al. Characterisation of an in vitro platelet function analyser, PFA-100TM. Clin Appl Thromb Hemost. 1996;2:241-249.
34. Marcucci R, Paniccia R, Antonucci E, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol. 2006;98:1156-1159.
35. Poulsen TS, Jørgensen B, Korsholm L, et al. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res. 2007;119:555-562.
36. Pamukcu B, Oflaz H, Onur I, et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coag Fibr. 2007;18:187-192.
37. Poulsen TS, Mickley H, Korsholm L, et al. Variation and importance of aspirin resistance in patients with known cardiovascular disease. Thromb Res. 2007;120:477-484.
38. Andersen K, Hurlen M, Arnesen H, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002;108:37-42.
39. Yilmaz MB, Balbay Y, Caldir V, et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res. 2005;115:25-29.
40. Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250: 63-66.
41. Gulmez O, Yildirir A, Kaynar G, et al. Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. J Thromb Thrombol. 2007 Jun 16 [Epub ahead of print].
42. Malek ŁA, Spiewak M, Filipiak KJ, et al. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Kardiol Pol 2007;65:40-45.
43. Pamukcu B, Oflaz H, Oncul A, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombol. 2006;22:103-110.
44. Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J. 2005;149:675-680.
45. Hobikoglu GF, Norgaz T, Aksu H, et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol. 2007;23: 201-206.
46. Borna C, Lazarowski E, van Heusden C, et al. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J. 2005;3:10.
47. Hobikoglu GF, Norgaz T, Aksu H, et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med. 2005;207:59-64.
48. Atiemo AD, Ng'alla LS, Vaidya D, et al. Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. J Thromb Thrombol. 2008;25:173-178.
49. Poston RS, Gu J, Brown JM, et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2006;131:122-130.
50. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78:1003-1007.
51. Buch AN, Singh S, Roy P, et al. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2007;99: 1518-1522.
52. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004; 43:1122-1126.
53. Harrison P, Segal H, Silver L, et al. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets. 2008;19:119-124.
54. Chakroun T, Addad F, Abderazek F, et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res. 2007;121:413-418.
55. Karon BS, Wockenfus A, Scott R, et al. Aspirin responsiveness in healthy volunteers measured with multiple assay platforms. Clin Chem. 2008 Apr 17 [Epub ahead of print].
56. Malinin AI, Ong S, Makarov LM, et al. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract. 2006;60:993-1002.
57. Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol. 2007;120:188-192.
58. Feher G, Koltai K, Papp E, et al. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging. 2006;23:559-567.
59. Stef G, Csiszar A, Lerea K, et al. Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovasc Pharmacol. 2006;48:1-5.
60. Stef G, Csiszar A, Ziangmin Z, et al. Inhibition of NAD(P)H oxidase attenuates aggregation of platelets from high-risk cardiac patients with aspirin resistance. Pharmacol Rep. 2007;59:428-436.
61. Poston RS, Gu J, White C, et al. Perioperative management of aspirin resistance after off-pump coronary artery bypass grafting: possible role for aprotinin. Transfusion. 2008;48(Suppl 1):39S-46S.
62. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002;107:45-49.
63. Eikelboom JW, Hankey GJ, Thom J, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J Thromb Haemost. 2005;3:2649-2455.
64. Dropinski J, Jakiela B, Sanak M, et al. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost. 2007l;98:201-209.
65. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27:2667-2674.
66. Task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology: Expert consensus document on the use of antiplatelet agents. Eur Heart J. 2004; 25:166-181.
67. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-1311.
68. Braunwald E, Angiolillo D, Bates E, et al. Assessing the current role of platelet function testing. Clin Cardiol 2008;31(Suppl 1):I10-I16.